Pulse Biosciences’ CellFX Nanosecond Pulsed Field Ablation (nsPFA™) Technology to be Featured in Several Presentations at The Heart Rhythm Society 2024 Annual Meeting
Pulse Biosciences' CellFX® Nanosecond Pulsed Field Ablation™ (nsPFA™) technology will be featured in several presentations at the Heart Rhythm Society 2024 Annual Meeting in Boston, MA, from May 16-19. The technology will be highlighted in six presentations and abstracts, including a live case presentation.
The preclinical and initial clinical results for CellFX nsPFA have shown promise, particularly in treating atrial fibrillation. The presentations will cover various aspects of the technology, including preclinical evaluations, first-in-human experiences, and novel catheter designs.
Prominent sessions include a live case demonstrating PVI+ with nsPFA, a presentation on the biophysical insights of novel ablation technologies, and multiple poster sessions on preclinical and clinical assessments of the technology.
- Pulse Biosciences' CellFX nsPFA technology to be featured in six presentations at a prestigious medical conference.
- Promising preclinical and initial clinical results for CellFX nsPFA, particularly in treating atrial fibrillation.
- Live case demonstration of PVI+ with nsPFA at the Heart Rhythm Society 2024 Annual Meeting.
- Multiple sessions and presentations by well-regarded medical professionals add credibility.
- Potential broad application for both cardiac surgeons and electrophysiologists, addressing diverse patient needs.
- No concrete financial data or revenue impact reported from these developments.
- Initial clinical results, while promising, are not yet definitive or peer-reviewed.
- Heavy reliance on conference presentations for technology validation may not translate directly into market performance.
“We look forward to our proprietary CellFX nsPFA technology being highlighted in six total presentations and abstracts, and in a live case presentation at the prestigious HRS meeting,” said Darrin Uecker, Chief Technology Officer and Director of Pulse Biosciences. “The preclinical and initial clinical outcomes from studies with our surgical clamp and catheter are encouraging and we continue to believe that CellFX nsPFA can meaningfully advance the treatment of atrial fibrillation.”
“Our innovative energy delivery platform technology allows us to uniquely meet the needs of both cardiac surgeons and EPs who together treat all types of patients with cardiac ailments,” added President and Chief Executive Officer Burke T. Barrett. “I am looking forward to speaking with, now as part of Pulse Biosciences, the many providers in the clinical community I have met over the years.”
CellFX nsPFA technology will be featured at the following times at the HRS 2024 Annual Meeting:
Thursday, May 16, 2024 |
|
PFA Live Case Summit |
|
Time: |
1:30pm to 3:00pm ET |
Location: |
Boston Convention & Exhibition Center, Room 210BC |
|
|
|
Session III - Live/Recorded PFA Cases |
|
Live Case: PVI+ with Nanosecond PFA (CellFX® nsPFA™; Pulse Biosciences) |
|
Live Case Site: Na Homolce Hospital |
|
Live Case Operators: Jan Petru, MD, and Moritoshi Funasako, MD, PhD |
|
|
Friday, May 17, 2024 |
|
Presentation | Understanding Novel Ablation Technologies: Insights from Biophysics and Preclinical Studies |
|
Time: |
1:25pm to 1:30pm ET |
Location: |
Moderated Poster Hub 3 - BCEC |
|
|
|
Nanosecond Pulsed Field Myocardial Ablation: Preclinical Evaluation using a Novel Catheter and Generator (MP-483493-002) |
|
Keita Watanabe, MD (presenting author), Moritz Nies, MD, Abhishek Mann, William Whang, MD, Srinivas R. Dukkipati, MD, Vivek Y. Reddy, MD, Jacob S. Koruth, MD |
Saturday, May 18, 2024 |
|
Presentation | Poster Session V - Ablation |
|
Time: |
1:30pm – 3:30pm ET |
Location: |
Abstract Pavilion - BCEC |
|
|
|
First-in-Human Clinical Experience of Pulse Field Ablation Using Nanosecond Pulses to Treat Atrial Fibrillation (PO-05-158) |
|
Vivek Y. Reddy, MD (presenting author), Jacob S. Koruth, MD, Jan Petru, MD, Moritoshi Funasako, MD, PhD, Pavel Hala, MD, Jan Skoda, MD, Petr Neuzil, MD, PhD |
|
|
Sunday, May 19, 2024 |
|
Presentation | Poster Session VI - Ablation |
|
Time: |
9:30am to 11:30am ET |
Location: |
Abstract Pavilion - BCEC |
|
|
|
Focal Nanosecond Pulsed Field Ablation: Preclinical Assessment of a Novel Catheter Tip Design (PO-06-142) |
|
Keita Watanabe, MD (presenting author), Moritz Nies, MD, Srinivas R. Dukkipati, MD, Marc A. Miller, MD, William Whang, MD, Joshua Lampert, MD, Vivek Y. Reddy, MD, Jacob S. Koruth, MD |
|
|
|
Exploring Esophageal Effects After Pulsed Field Ablation: Preclinical Evaluation of Nanosecond Pulse using a Dedicated Endocardial System (PO-06-151) |
|
Jacob S. Koruth, MD (presenting author), Moritz Nies, MD, Keita Watanabe, MD, Daniel Musikantow, Mohit Turagam, Joshua Lampert, MD, Marc A. Miller, MD, Vivek Y. Reddy, MD |
|
Performance of the First Bipolar Nanosecond Pulsed Field Ablation (nsPFA) Clamp in a Chronic Porcine Model (PO-06-152) |
|
Gansevoort Hurlbut Dunnington, MD (presenting author), Swami Gnanashanmugam, David Danitz, MSME, Lauren Johnston, Darrin Uecker, MSEE, Jeffrey Litt, Anita Crompton, Mike Smith, Ilya Getsin, Niv Ad, MD |
|
|
|
Ultrafast Delivery of Consistent Endocardial and Epicardial Transmural Ablation Lesions Using a New Nanosecond Pulsed Field Ablation (nsPFA) Platform (PO-06-153) |
|
Gansevoort Hurlbut Dunnington, MD (presenting author), Chad Brodt, Swami Gnanashanmugam, David Danitz, MSME, Lauren Johnston, Darrin Uecker, MSEE, Jeffrey Litt, Anita Crompton, Roman Turovskiy, Ilya Getsin, Niv Ad, MD |
About Pulse Biosciences®
Pulse Biosciences is a novel bioelectric medicine company committed to health innovation that has the potential to improve the quality of life for patients. The Company’s proprietary CellFX® nsPFA™ technology delivers nanosecond pulses of electrical energy to non-thermally clear cells while sparing adjacent noncellular tissue. The Company is actively pursuing the development of its CellFX nsPFA technology for use in the treatment of atrial fibrillation and in a select few other markets where it could have a profound positive impact on healthcare for both patients and providers.
Pulse Biosciences, CellFX, Nano-Pulse Stimulation, NPS, nsPFA, CellFX nsPFA and the stylized logos are among the trademarks and/or registered trademarks of Pulse Biosciences, Inc. in
Forward-Looking Statements
All statements in this press release that are not historical are forward-looking statements, including, among other things, statements relating to the potential effectiveness and uniqueness of the Company’s CellFX nsPFA technology to treat cardiac ailments, statements concerning pre-clinical or early clinical successes and whether they are predictive of the safety and efficacy of any medical device, and the Company’s expectations, whether stated or implied, regarding whether the Company’s CellFX nsPFA technology will become a disruptive and durable treatment option for treating any medical condition, and other future events. These statements are not historical facts but rather are based on Pulse Biosciences’ current expectations, estimates, and projections regarding Pulse Biosciences’ business, operations and other similar or related factors. Words such as “may,” “will,” “could,” “would,” “should,” “anticipate,” “predict,” “potential,” “continue,” “expects,” “intends,” “plans,” “projects,” “believes,” “estimates,” and other similar or related expressions are used to identify these forward-looking statements, although not all forward-looking statements contain these words. You should not place undue reliance on forward-looking statements because they involve known and unknown risks, uncertainties, and assumptions that are difficult or impossible to predict and, in some cases, beyond Pulse Biosciences’ control. Actual results may differ materially from those in the forward-looking statements as a result of a number of factors, including those described in Pulse Biosciences’ filings with the Securities and Exchange Commission. Pulse Biosciences undertakes no obligation to revise or update information in this release to reflect events or circumstances in the future, even if new information becomes available.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240516957050/en/
Investor Contacts:
Pulse Biosciences, Inc.
Burke T. Barrett, President and CEO
IR@pulsebiosciences.com
Or
Gilmartin Group
Philip Trip Taylor
415.937.5406
philip@gilmartinir.com
Source: Pulse Biosciences, Inc.
FAQ
What is Pulse Biosciences' CellFX nsPFA technology?
When will Pulse Biosciences present its CellFX nsPFA technology at the Heart Rhythm Society 2024 Annual Meeting?
What are the key highlights of Pulse Biosciences' involvement in the Heart Rhythm Society 2024 Annual Meeting?
What is the significance of the live case demonstration for Pulse Biosciences' CellFX nsPFA technology?
Who are some of the key presenters for Pulse Biosciences at the Heart Rhythm Society 2024 Annual Meeting?
